EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial

Rachel Gologorsky, Maarten G Lansberg iD, Max Wintermark iD, Christy N Cassarly iD, Rebeca Aragon Garcia, Pamela Plummer, Nilushi Karunamuni, Scott E Kasner iD, Babak B Navi iD, Ava Liberman iD, Mukul Sharma iD, Joseph P Broderick iD und 6 weitere

Stroke · 2026

DOI: 10.1161/strokeaha.125.053079 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Stroke, 2026. Verfasst von Rachel Gologorsky und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, NY (…. Hauptthemen laut MEDLINE: Anticoagulants, Ischemic Stroke, Brain Infarction. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with cryptogenic stroke, the characteristics of multiterritory brain infarcts, the recurrent stroke risk, and the response to anticoagulation remain unclear. METHODS: The ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) screened patients with cryptogenic stroke for atrial cardiopathy at 185 centers in the United States and Canada from 2018 to 2022. Investigators reported baseline acute brain infarction in the left anterior, right anterior, and posterior circulation. Atrial cardiopathy was defined as P-wave terminal force in ECG lead V1s >5000 μV·ms, NT-proBNP (N-terminal pro-B-type natriuretic peptide) >250 pg/mL, or left atrial diameter index ≥3 cm/m 2 . Site echocardiography laboratories determined left atrial diameter index and a central echocardiography laboratory determined LVEF. We used ANCOVA to examine whether atrial cardiopathy biomarkers or LVEF were associated with the number of territories with infarction. Cox regression was used to examine whether the number of infarct territories was associated with recurrent stroke or modified the effect of apixaban compared with aspirin. RESULTS: Among 3464 patients with reported baseline magnetic resonance imaging data, 220 (6.4%) had no visible acute infarct and 2794 (80.7%) had acute infarction in 1, 374 (10.8%) in 2, and 76 (2.2%) in 3 territories. Atrial cardiopathy biomarkers and LVEF were not associated with the number of infarct territories. Among 937 of these 3464 patients who were randomized, we found higher risks of recurrent stroke associated with infarcts in 2 territories (hazard ratio, 2.4 [95% CI, 1.3–4.2]) or 3 territories (hazard ratio, 3.7 [95% CI, 1.5–9.3]) relative to single-territory infarction, whereas the absence of visible infarction was not associated with recurrence (hazard ratio, 1.8 [95% CI, 0.6–4.9]). The number of infarct territories did not modify the effect of apixaban versus aspirin in relation to recurrent stroke ( P for interaction, 0.71). CONCLUSIONS: Multiterritory brain infarction was not associated with atrial cardiopathy biomarkers or LVEF in the ARCADIA trial. Multiterritory infarction was associated with a significantly higher risk of recurrent stroke, but this heightened risk was not reduced by apixaban relative to aspirin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsIschemic StrokeBrain InfarctionHumansMaleFemaleAgedRecurrenceMiddle AgedAspirinPyridonesPyrazolesNatriuretic Peptide, BrainFactor Xa InhibitorsAtrial Fibrillation

Stichwörter der Autor:innen

anticoagulantapixabanaspirinatrial fibrillationcardiopathies

Substanzen

AnticoagulantsapixabanAspirinPyridonesPyrazolesNatriuretic Peptide, BrainFactor Xa Inhibitors

Autor:innen und Institutionen

  • Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, NY (R.G., N.K., B.B.N., A.L., H.K.).
  • Department of Neurology and Neurological Sciences, Stanford Stroke Center, Stanford University, Palo Alto, CA (M.G.L.).
  • Department of Neuroradiology, University of Texas, Austin (M.W.).
  • MD Anderson Center, Houston, TX (M.W.).
  • Department of Public Health Sciences, Medical University of South Carolina, Charleston (C.N.C.).
  • Department of Neurology, Vagelos College of Physicians and Surgeons, New York, NY (R.A.G., M.S.V.E.).

ORCID-Profile: Maarten G Lansberg, Max Wintermark, Christy N Cassarly, Scott E Kasner, Babak B Navi, Ava Liberman, Mukul Sharma, Joseph P Broderick, David L Tirschwell, Richard A Kronmal, Mitchell S V Elkind, Hooman Kamel

Förderung

  • NINDS NIH HHS

Zitieren

APA

Gologorsky, R., Lansberg, M. G., Wintermark, M., Cassarly, C. N., Aragon Garcia, R., Plummer, P., Karunamuni, N., Kasner, S. E., Navi, B. B., Liberman, A., Sharma, M., Broderick, J. P., Longstreth, W. T., Tirschwell, D. L., Kronmal, R. A., Elkind, M. S. V., Kamel, H., & ARCADIA Investigators (2026). Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial. Stroke. https://doi.org/10.1161/strokeaha.125.053079

Vancouver

Gologorsky R, Lansberg MG, Wintermark M, Cassarly CN, Aragon Garcia R, Plummer P, et al. Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial. Stroke. 2026. doi:10.1161/strokeaha.125.053079

BibTeX
@article{Gologorsky2026,
  author = {Gologorsky, Rachel and Lansberg, Maarten G and Wintermark, Max and Cassarly, Christy N and Aragon Garcia, Rebeca and Plummer, Pamela and Karunamuni, Nilushi and Kasner, Scott E and Navi, Babak B and Liberman, Ava and Sharma, Mukul and Broderick, Joseph P and Longstreth, W T and Tirschwell, David L and Kronmal, Richard A and Elkind, Mitchell S V and Kamel, Hooman and ARCADIA Investigators, ARCADIA Investigators},
  title = {Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial},
  journal = {Stroke},
  year = {2026},
  doi = {10.1161/strokeaha.125.053079}
}
Kostenlos starten →